Abstract

Background: Currently endoscopy examination takes an important role in the diagnosis of colorectal cancer, and there are no other clinically viable noninvasive diagnostic methods.  In this investigation, a newly developed, novel IVD cancer diagnostic technology named Cancer Differentiation Analysis (CDA) Technology was investigated for colorectal cancer diagnosis.  CDA is a new technology using multi-level and multi-parameter information which measures information relating to both protein fragments and cellular signals in blood samples in one single test.

Methods: Peripheral blood was drawn in EDTA tubes for CDA tests. Intravenous blood samples from individuals with colorectal cancer (n = 193), as well as control samples (n = 705) were collected. Cancer group has been clinically diagnosed, and individuals in control group have been confirmed by physical examinations free of cancer. All blood samples were tested using a CDA device, and collected data were analyzed in the SPSS Packages. 

Results: Data analysis (using T test) showed a significant statistical difference with P value < 0.05 between colorectal cancer group and control group. Details of CDA test results were given in Table 1. Based on initial data, the area under curve (AUC), sensitivity and specificity of CDA technology for colorectal cancer were determined to be 0.861, 76.7% and 76.7% (cut-off value was set at a level at which sensitivity and specificity are comparable), respectively.
Conclusions: CDA technology is able to statistically distinguish control group from colorectal cancer group with reasonably high sensitivity and specificity (both above 75%).  As a non-invasive and potentially cost effective method capable of large population screening, CDA technology could be a very promising approach for the screening and diagnosis of colorectal cancer.

• Gastrointestinal Cancers Symposium (San Francisco). 2017. Prevention, Diagnosis, and Screening. Category : Prevention, Diagnosis, and Screening. Session Type and Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus. Abstract Number: 564. Poster Board Number: Poster Session C Board #C4.
  Author(s):Hongmei Tao, Xuedong Du, Shijin Ding, Xing Tang, Da Lou, Yue Lin, Chris Chang Yu; AnPac Bio-Medical Science and Technology Co., LTD, Shanghai, China; Anpac Bio-Medical Science Technology Co., Ltd., Shanghai, China; Anpac Bio-Medical Science Co., Ltd., Shanghai, China; Anpac Bio-Medical Science Co Ltd, Shanghai, China